At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AVTE Aerovate Therapeutics, Inc.
Post-Market Trading 11-07 18:28:41 EST
2.74
-0.02
-0.72%
盘后2.70
-0.04-1.46%
16:44 EST
High2.80
Low2.71
Vol315.03K
Open2.78
D1 Closing2.76
Amplitude3.26%
Mkt Cap79.10M
Tradable Cap32.46M
Total Shares28.87M
T/O866.56K
T/O Rate2.66%
Tradable Shares11.85M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
M&A deals roundup: AbbVie, Blackstone, Take-Two Interactive and more
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.